|
MCCC2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.55430004609303E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.70279999492473E-08 |
| Normal-vs-Stage2 |
8.940800E-01 |
| Normal-vs-Stage3 |
2.59369969946022E-10 |
| Normal-vs-Stage4 |
1.44959999559546E-09 |
| Stage1-vs-Stage2 |
1.220390E-03 |
| Stage1-vs-Stage3 |
9.228000E-02 |
| Stage1-vs-Stage4 |
1.013200E-01 |
| Stage2-vs-Stage3 |
1.440010E-04 |
| Stage2-vs-Stage4 |
1.613560E-04 |
| Stage3-vs-Stage4 |
9.351800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.12860054635178E-10 |
| Normal-vs-AfricanAmerican |
6.799100E-03 |
| Normal-vs-Asian |
1.61100000006797E-08 |
| Caucasian-vs-AfricanAmerican |
1.369170E-01 |
| Caucasian-vs-Asian |
7.138000E-01 |
| AfricanAmerican-vs-Asian |
1.068590E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.11260000002345E-07 |
| Normal-vs-Female |
1.74769999583546E-08 |
| Male-vs-Female |
8.829600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.20570000836796E-09 |
| Normal-vs-Age(41-60Yrs) |
6.90350000498441E-08 |
| Normal-vs-Age(61-80Yrs) |
1.374690E-04 |
| Normal-vs-Age(81-100Yrs) |
2.064000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.442800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.343600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.033000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.647800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.671800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.138400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.47089999999961E-05 |
| Classical-VS-Follicular |
7.67830243830758E-11 |
| Classical-VS-Other |
6.187600E-01 |
| Classical-VS-Normal |
1.68520752907853E-12 |
| Tall-VS-Follicular |
1.62847513252018E-12 |
| Tall-VS-Other |
2.326800E-01 |
| Tall-VS-Normal |
8.88178419700125E-16 |
| Follicular-VS-Other |
8.06389999999935E-05 |
| Follicular-VS-Normal |
3.836400E-01 |
| Other-VS-Normal |
6.951600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.71689999999881E-05 |
| Normal-vs-N1 |
3.69519970178089E-11 |
| N0-vs-N1 |
1.951970E-04 |
|
|
